Influenza is constantly developing new viral strains, which in turn requires the constant development of updated flu vaccines. To keep up, the AMA publishes new and revised vaccine codes twice per year, and when required for emergent/critical distribution.
Two new influenza vaccine codes are available for use Feb. 1, 2015:
- CPT 90620 Meningococcal recombinant protein and outer membrane vesicle vaccine, Serogroup B, 2 dose schedule, for intramuscular use
- CPT 90621 Meningococcal recombinant lipoprotein vaccine, Serogroup B, 2 or 3 dose schedule, for intramuscular use
Additionally, the vaccine described by CPT 90630 Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, for intradermal use has achieved FDA approval.
Although not an influenza vaccine, CPT 90697 Diphtheria, tetanus toxoids, acellular pertussis vaccine, inactivated poliovirus vaccine, Haemophilus influenza type b PRP-OMP conjugate vaccine, and hepatitis B vaccine (DTaP- IPV-Hib-HepB), for intramuscular use will be active as of Jan. 1, 2015.
An additional 48 vaccine codes in the CPT 90632 – CPT 90748 range also are revised, effective July 2015. The minor descriptor revisions clarify terminology, but do not change proper code application. Additional format edits are also included for CPT 90647, CPT 90648, CPT 90696, CPT 90702, CPT 90714, and CPT 90721.